1. Scrip
  2. >>Therapy Areas

Ferring Plots Genomics Path With Celmatix Pact

 
• By Kevin Grogan

The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.

DNA
Partners adopt a genomics approach to improving IVF • Source: Shutterstock

Ferring Pharmaceuticals AS has turned to the US women's health genomics company Celmatix to help generate new insights into ovarian biology that could speed up personalized care in reproductive medicine and women’s health.

Speaking to Scrip, Ferring's chief medical officer Klaus Dugi said the aim of the collaboration is to use Celmatix’s large-scale datasets to explore whether women’s responses to ovarian stimulation during...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.